Pressmeddelanden, rapporter och bolagsmeddelande för Curasight

Curasight har meddelat att de har lämnat in en ansökan via Clinical Trials Information System (CTIS) för att påbörja en fas 1-studie av uTREAT, en ny typ av riktad strålbehandling för patienter med glioblastom, en aggressiv form av hjärncancer. Studien syftar till att undersöka säkerheten och effektiviteten hos uTREAT. Curasight hoppas att uTREAT kan bli en banbrytande behandling för denna cancerform, som har en mycket dålig prognos och där det finns ett stort medicinskt behov av nya behandlingar. Curasight har också utvecklat uTRACE, en teknik för känslig bilddiagnostik, som tillsammans med uTREAT utgör en integrerad plattform för att förbättra diagnos och behandling av cancer som uttrycker uPAR-receptorn. Glioblastom och andra höggradiga gliom har en mycket låg överlevnadsgrad, och det finns ett stort behov av nya, effektiva behandlingar.

Curasight is required by its articles of association to execute the TO3 warrants at a minimum price of DKK 15.55, which is above the current market price. The board does not expect these warrants to be exercised. In September 2024, Curasight issued 1,841,907 TO3 warrants through a rights issue and a directed issue. Each warrant allows the holder to subscribe for one new share between 4 June 2025 and 18 June 2025, at a price of DKK 15.55 per share. If fully utilized, this would raise approximately DKK 28.6 million before costs, increase the share count to 47,705,917, and raise the share capital by DKK 92,095.35, resulting in a dilution of about 3.9%. Key dates include the start of the exercise period on 4 June 2025, the last trading day on 16 June 2025, the end of the exercise period on 18 June 2025, publication of the outcome on 23 June 2025, and the change from interim shares to shares on 2 July 2025. Sedermera Corporate Finance AB, DLA Piper, and Danske Bank are advising Curasight on this process.

In connection with the Rights Issue, it was announced that guarantee commitments totaling approximately DKK 19.3 million were involved. Guarantors could receive a 13% cash compensation or 22% in newly issued shares. Those opting for cash compensation will receive about DKK 1.36 million. The Directed Issue deviates from shareholders' preferential rights to meet contractual obligations to guarantors. The Board sees issuing new shares as beneficial for the company's financial position. The Directed Issue was authorized at an Extraordinary General Meeting on April 23, 2025, with a subscription price of DKK 1.98 per share, set through negotiations. Payment will offset guarantee claims. The Directed Issue increases share capital by DKK 48,888.40, raising the total number of shares by 977,768 to 45,864,010, resulting in a 2.1% dilution. Sedermera Corporate Finance AB is the Sole Global Coordinator, with DLA Piper as legal advisor and Danske Bank A/S as settlement agent. For more information, contact Sedermera Corporate Finance AB or Ulrich Krasilnikoff, CEO of Curasight A/S.

The registration of new shares from the Rights Issue has been completed with the Danish Business Authority. A total of 23,737,362 shares were subscribed, including a guarantee subscription, increasing the company's share capital by DKK 1,186,868.10. Curasight's share capital now totals DKK 2,244,312.10, equivalent to 44,886,242 shares, with each share valued at DKK 0.05. The new shares are expected to begin trading on June 6, 2025, and convert to ordinary shares by June 10, 2025. Sedermera Corporate Finance AB is the global coordinator and bookrunner, DLA Piper is the legal advisor, and Danske Bank A/S is the settlement agent. For more information, contact Sedermera Corporate Finance AB or Ulrich Krasilnikoff, CEO of Curasight A/S.

At Curasight's Annual General Meeting, several resolutions were passed. The shareholders reviewed and approved the Board of Directors' report on the company's activities and the annual report for 2024. The decision was made to carry forward the profit for 2024 to the next year. The existing board members were re-elected, including Kirsten Aarup Drejer as chairman and Lars Trolle as vice-chairman. PricewaterhouseCoopers was re-elected as the auditor. A proposal to authorize the issuance of up to 7,100,000 warrants for directors, executives, and key employees was approved, with the authorization valid until May 28, 2030. Additionally, the chairman of the meeting, Ulrik Bangsbo Hansen, was authorized to register these resolutions. The updated articles of association and meeting minutes will be available on the company's website.

Curasight's CEO, Ulrich Krasilnikoff, expressed satisfaction with the company's ability to secure new capital amid challenging market conditions, enabling the continued development of cancer treatment options uTRACE® and uTREAT®. The company welcomed new strategic shareholders, Curium and Pentwater, and aims to focus on key clinical milestones, including the completion of a Phase II study on prostate cancer and the initiation of a Phase I study on aggressive brain cancer. The Rights Issue concluded with approximately 47% of shares subscribed, involving 23,737,362 shares, with guarantors covering the shortfall. The company's share capital increased, leading to a 52.9% dilution. Krasilnikoff and Andreas Kjær saw changes in their ownership percentages, while Curium and Pentwater became significant shareholders. No interim share trading will occur, and Sedermera Corporate Finance AB, DLA Piper, and Danske Bank A/S are involved as advisors. The announcement includes legal disclaimers and notes potential risks in forward-looking statements.

Översikten presenterar transaktioner kopplade till deltagande i "Right Issue 2025" för bolaget Curasight. Fem personer från företagets ledning och styrelse deltog, inklusive styrelseordföranden Kirsten Drejer, vice ordföranden Lars Trolle, VD och CFO Ulrich Krasilnikoff, CMO och CSO Andreas Kjær, samt medgrundaren Jacob Madsen. Sammanlagt köptes 2,712,328 nya aktier till ett totalt värde av 5,370,409.44 DKK. För mer information om Curasight kan Ulrich Krasilnikoff kontaktas via telefon eller e-post.

The agenda for Curasight's Annual General Meeting includes several key items. The Board of Directors will report on the company's activities over the past financial year and seek approval for the annual report. They propose that the 2024 financial results be carried forward to the next year. The meeting will also involve the election of board members, with proposals for re-election of current members, and the re-election of PricewaterhouseCoopers as the company's auditor. There are proposals for new resolutions, including the introduction of an incentive program involving the issuance of up to 7,100,000 warrants to key personnel, which aims to align their interests with those of the shareholders. This program is designed to retain and attract talent and is seen as strategically important for the company's growth. The warrants will be issued at market value, and the program may result in a 10% dilution of the company's share capital. The Board also seeks authorisation for the chairman to register the resolutions and make necessary amendments as required by authorities. Most agenda items require a simple majority vote, while the incentive program requires a two-thirds majority. Shareholders have rights to attend, vote, and submit questions at the meeting. Information and documents related to the meeting are available on the company's website. The meeting will be conducted in Danish.

Ingen prospekt har upprättats för den aktuella företrädesemissionen. Företaget har istället tagit fram ett informationsdokument enligt artikel 1.4 db) i EU-förordningen 2024/2809, som finns tillgängligt på företagets webbplats. Dokumentet ger mer information om företrädesemissionen och företaget och följer bilaga IX i prospektförordningen (EU) 2017/1129. Viktiga datum inkluderar handel med teckningsrätter från 30 april till 14 maj 2025, teckningsperiod från 2 maj till 16 maj 2025, och det förväntade publiceringsdatumet för resultatet den 21 maj 2025. Sedermera Corporate Finance AB är global koordinator och bokförare, DLA Piper är juridisk rådgivare, och Danske Bank A/S är avvecklingsagent. Kontakter för mer information är tillgängliga för både företrädesemissionen och företaget.

The Phase 1 trial is a significant step for Curasight in advancing its theranostic platform and establishing itself as a therapeutic company. Curasight is collaborating with Premier Research, a Clinical Research Organization experienced in international diagnostic and therapeutic trials with radiopharmaceutical agents, to ensure the trial's efficient execution. The trial aims to investigate Curasight’s uTREAT ligand as a treatment for Glioblastoma patients scheduled for brain surgery. The trial design is based on previous research and discussions with experts. Curasight's uTREAT platform is part of its uPAR theranostic solution, which includes uTRACE for diagnostics and uTREAT for targeted treatment in brain cancer. Premier Research specializes in clinical trial management, particularly in oncology and neuroscience. For more information, contact Curasight's CEO, Ulrich Krasilnikoff.